GLP‑1 treatment in Connecticut
Who ships GLP-1 medication to Connecticut, what Medicaid covers, and the telehealth rules that apply.
What the federal data shows for Connecticut
3,641 clinicians in Connecticut prescribed Ozempic to Medicare Part D patients in 2024, across 138,165 claims. That is the most-prescribed GLP-1 in the state by prescriber count. Part D covers Medicare only, so the figure is a floor on prescribing in Connecticut rather than a total.
Connecticut Medicaid reimbursed $45,098,362.27 for 35,563 GLP-1 prescriptions in Q1 2026, or $1,268.13 per prescription. From CMS State Drug Utilization, fee-for-service and managed care combined. Suppressed cells are excluded, never counted as zero.
2 outsourcing facilities registered with the FDA under section 503B give a Connecticut address, and 0 of them have no recorded FDA inspection. Registration is a filing, not an approval, and an uninspected facility has not passed an inspection — it has not had one. Each one has a page in the 503B register.
What is on this page
- 7 drug cost pages for Connecticut, each pairing the state's Medicaid figures with pharmacy acquisition cost
- 2 city pages showing where GLP-1 prescribers practise in Connecticut
- Every link below is a page for Connecticut specifically, not a national page filtered to it
- CMS NADACNational Average Drug Acquisition Cost, weekly file
- CMS Medicare Part DPrescriber public use file, by geography and drug
- CMS State Drug UtilizationQuarterly Medicaid prescription and reimbursement data
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.